Intellia Therapeutics (NTLA) Morgan Stanley 24th Annual Global Healthcare Conference summary
Event summary combining transcript, slides, and related documents.
Morgan Stanley 24th Annual Global Healthcare Conference summary
14 Sep, 2026Platform and pipeline overview
Pioneered in vivo gene editing, focusing on delivery challenges and leveraging lipid nanoparticle technology for liver-targeted therapies.
Advanced to late-stage trials for HAE and TTR cardiomyopathy/polyneuropathy, with ongoing efforts to expand delivery beyond the liver to organs like the brain and lung.
Emphasis on commercializing the first CRISPR-based therapy and validating the platform's potential.
HAE program and commercialization plans
BLA for HAE therapy accepted by FDA, with priority review and a PDUFA date set for March 10; no advisory committee planned.
Phase III data show strong efficacy (87% attack rate reduction, 62% attack-free at 28 weeks) and a clean safety profile.
Broad patient inclusion in trials, with expectations for a wide label excluding only those under 16.
Market access work ongoing, with payer discussions focused on pricing multiples and the therapy's durability; patient advocacy and education are key.
Commercial footprint will be targeted, with 250 prescribers covering half of U.S. patients; field force and infrastructure are being built out in anticipation of approval.
Launch dynamics and financial outlook
Launch expected to be gradual, with revenue ramping over several quarters; early metrics will focus on treatment center penetration and patient starts.
Even a moderate launch could cover operating costs, enabling reinvestment in pipeline programs.
Strong cash position ($630M as of Q2) and a new $300M debt facility provide flexibility; runway extends into 2028 without HAE revenue.
Latest events from Intellia Therapeutics
- Lonvo-z approaches a 2027 decision as launch planning and TTR trials advance.NTLA
Jefferies Global Healthcare Conference - Lonvo-z showed durable HAE control as FDA review and launch preparations advance.NTLA
Study update - Lonvo-z Priority Review targets a Q1 2027 launch amid continued losses and nex-z safety monitoring.NTLA
Q3 2026 - Strong Phase 3 data and $628.4M cash position support launch plans and ongoing clinical progress.NTLA
Q2 2026 - Accelerated phase III progress in ATTR and HAE, with major data and milestones expected by 2027.NTLA
BofA Securities 2025 Healthcare Conference - Nexi/nex-z achieved deep, durable TTR reduction and clinical stabilization in ATTR amyloidosis.NTLA
Study Update - Strong CRISPR trial progress, $944.7M cash, Q3 net loss $135.7M, late-stage pipeline advancing.NTLA
Q3 2024 - A single 50 mg dose achieved 81% attack reduction and 73% attack-free rate in HAE patients.NTLA
Study Update - Late-stage pipeline progress, restructuring, and cash runway extend operational momentum into 2027.NTLA
Q4 2024